Avelox is an antibacterial drug.
Release form and composition
- Avelox tablets containing moxifloxacin 400 mg. Auxiliary components of the tablets are microcrystalline cellulose, lactose monohydrate, magnesium stearate, croscarmellose sodium. In blister packs of 5 or 7 tablets;
- Solution for infusions Aveloks containing 400 mg of moxifloxacin. Auxiliary substances of the solution are sodium chloride, sodium hydroxide solution, hydrochloric acid. In bottles of 250 ml.
Indications for use of Avelox
According to the instructions, Avelox is prescribed in the presence of infectious and inflammatory diseases, such as:
- Exacerbation of chronic bronchitis;
- Acute sinusitis;
- Uncomplicated infections of soft tissue and skin;
- Community-acquired pneumonia;
- Complicated intra-abdominal infections, including polymicrobial infections and intraperitoneal abscesses;
- Complicated infections of the skin and subcutaneous structures (including an infected diabetic foot);
- Inflammatory diseases of the pelvic organs (endometritis, salpingitis, etc.).
According to the instructions, Avelox should not be taken:
- Patients with congenital or acquired prolongations of the QT interval, clinically significant bradycardia, electrolyte disorders (especially with uncorrected hypokalemia), clinically significant heart failure, accompanied by a reduced left ventricular ejection fraction, and rhythm disorders in history;
- With a history of tendon pathology, which developed as a result of quinolone antibiotic therapy;
- In combination with drugs that extend the QT interval;
- With congenital lactose intolerance, lack of lactase, glucose-galactose malabsorption;
- When violations of liver function and patients who have an increase in liver transaminases more than 5 times higher than the level of VGN;
- During pregnancy and breastfeeding;
- Under the age of 18;
- When hypersensitivity to the current or auxiliary components of the drug.
When using Avelox, care should be taken in the following cases:
- Central nervous system diseases predisposing to the development of convulsive seizures or reducing the threshold of convulsive readiness;
- Proarrhythmic conditions, including acute myocardial ischemia (especially in elderly patients and women);
- Cirrhosis of the liver;
- Combination with drugs that reduce the level of potassium in the body.
Administration and dosage of Avelox
According to the instructions, Avelox is shown inside and intravenously. The dosage of the drug is 400 mg per day.
With internal or intravenous administration, the duration of treatment with Avelox is:
- Exacerbation of chronic bronchitis - 5-10 days;
- Community-acquired pneumonia - 1-2 weeks intravenously, then 1.5 weeks inside;
- Acute sinusitis and uncomplicated infections of soft tissues and skin - 1 week;
- Complicated infections of the skin and subcutaneous tissues - 1-3 weeks;
- Complicated intra-abdominal infections - 5-14 days;
- Uncomplicated inflammation of the pelvic organs - 2 weeks.
As a rule, the duration of use of Avelox does not exceed 21 days (3 weeks).
According to the instructions, Avelox tablets are taken whole, not chewed and squeezed with a small amount of liquid. Drug intake does not depend on meals. The recommended dose should not be exceeded.
The solution for infusion of Avelox is administered intravenously over 1 hour. Drug administration is allowed both in diluted and in concentrated form using a T-shaped adapter.
Avelox solution can be diluted with 0.9% sodium chloride solution, water for injection, 5, 10 or 40% dextrose solution, 20% xylitol solution, Ringer's solution, Ringer-lactate solution.
After dilution with solvents, Avelox's solution can be stored for no longer than a day at room temperature.
In the case when Avelox solution is prescribed as part of a combination therapy, each drug is recommended to be administered separately.
Side effects of Avelox
The use of Avelox can cause the following side effects:
- Hematopoietic system: leukopenia, anemia, neutropenia, prolongation of prothrombin time, thrombocytopenia, changes in the concentration of thromboplastin, an increase in INR;
- Infections: fungal infections;
- Immune system: allergic reactions in the form of skin rash, itching, urticaria, eosinophilia, as well as anaphylactic reactions, angioedema, anaphylactic shock;
- Metabolism: hyperuricemia, hyperglycemia, hyperlipidemia;
- Mental disorders: anxiety, agitation, psychomotor hyperreactivity, depression, emotional lability, psychotic reactions, depersonalization;
- Central and peripheral nervous systems: headache, dizziness, disorientation, confusion, drowsiness, vertigo, tremor, atypical dreams, paresthesias, disturbance of taste, impaired coordination of movements;
- Vision organs: visual impairment, transient loss of vision;
- Organs of hearing: impairment of hearing, tinnitus;
- Cardiovascular system: prolongation of the QT interval, elevation of blood pressure, ventricular tachyarrhythmias, syncope;
- Others: vomiting, nausea, sweating, arthritis, general malaise, stomatitis, pseudomembranous colitis.
Moxifloxacin - the active ingredient of Avelox - affects the ability of a person to control potentially dangerous mechanisms, as it can cause impairment of vision, hearing and affect the central nervous system.
Analogs of Avelox
Structural analogues of Avelox are drugs Moxifloxacin, Moxin, Moximac, Plevilox.
Terms and conditions of storage
According to the instructions, Aveloks should be stored in a dry place at a temperature of 8-25 ° C.
Avelox solution should not be stored for more than 3 years, tablets - no longer than 5 years.